{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    7,
    23,
    43
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_18",
        "affectedSection": "Multiple Sections",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated protocol to reflect most recent guidance for treating study participants with nivolumab and added exploratory objective."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_18",
        "affectedSection": "Study Objectives and Endpoints",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addressed minor inconsistencies in study objectives and endpoints."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_16",
        "affectedSection": "Section 1.4 - Objectives",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Changed Overall Response Rate (ORR) from a co-primary objective to a secondary objective."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_11",
        "affectedSection": "Section 1.4 - Objectives",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Changed co-primary endpoint from time to progression (TTP) to objective response rate (ORR)."
      },
      {
        "id": "impact_5",
        "amendmentId": "admin_03",
        "affectedSection": "Laboratory Procedures",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified Hepatitis D testing options for local vs central labs."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_18",
        "reasonText": "Reflect most recent guidance for treating study participants with nivolumab",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_18",
        "reasonText": "Evaluating the correlation of tumor inflammation with efficacy based on recent preliminary data",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_16",
        "reasonText": "Re-prioritization of study endpoints to make Overall Survival (OS) the sole primary endpoint",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "admin_04",
        "reasonText": "Update overall alpha in Section 8.4.2.1",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_16",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.4",
        "beforeText": "Overall Response Rate (ORR) as a co-primary objective",
        "afterText": "Overall Response Rate (ORR) as a secondary objective; Overall Survival (OS) as the sole Primary Endpoint",
        "summary": "Downgraded ORR from co-primary to secondary endpoint."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_18",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.4",
        "afterText": "Exploratory objective evaluating the correlation of tumor inflammation with efficacy",
        "summary": "Added new exploratory objective based on preliminary data."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_11",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "3.1",
        "afterText": "Requirement for confirmatory scan to be performed for CR/PR assessment of best overall response (BOR)",
        "summary": "Added requirement for confirmatory scans for response assessment."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_02",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "3.3",
        "beforeText": "Standard HCV RNA testing frequency",
        "afterText": "Reduction of frequency of HCV RNA testing for HCV infected subjects",
        "summary": "Decreased frequency of HCV RNA monitoring."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_11",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.5.3",
        "beforeText": "Previous management algorithms",
        "afterText": "Management algorithms updated per revised nivolumab IB",
        "summary": "Updated safety management algorithms to align with the latest Investigator Brochure."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}